Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple Sclerosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001643-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in new contrast-enhancing lesions (CELs) in RRMS patients To evaluate mutiple doses of vatelizumab for a dose-response.


Critère d'inclusion

  • Nervous System Diseases